Skip to main content
To the Editor: Somnambulism has been reported with the use of classical antipsychotics (1). However, to our knowledge, there have been no reports of somnambulism associated with the use of atypical antipsychotics. We present two cases of somnambulism induced by olanzapine in patients with no previous history of somnambulism despite several years of antipsychotic pharmacotherapy.
Mr. A was a 63-year-old man with a 41-year history of schizophrenia who was seen as an outpatient in a specialized clinic for schizophrenia. He had taken risperidone for several years but was switched to olanzapine, which was increased over 10 months to 20 mg at bedtime. After 1 week at this dose, he complained of sleepwalking most nights, during which no injuries occurred. The sleepwalking was witnessed by a roommate. Mr. A’s olanzapine dose was gradually decreased over 6 months, and he began taking risperidone. Even when he was taking only 5 mg of olanzapine, his sleepwalking persisted, but it ceased immediately when he stopped taking it. He reported no personal or family history of epilepsy, somnambulism, or other parasomnias. A computerized tomography scan of his head and EEG were normal. His other medications included valproate, 1750 mg/day, and procyclidine, 15 mg/day.
Ms. B was a 62-year-old woman with a 35-year history of schizophrenia who was being treated with loxapine. She started taking olanzapine and reached a maximum dose of 20 mg at bedtime. She then reported sleepwalking for 6 months. Valproate was added to her medication regimen, but her somnambulism persisted. She was switched from olanzapine to risperidone over 3 months; the somnambulism decreased in frequency with tapering doses and ceased after discontinuation of olanzapine.
Somnambulism arises during slow-wave sleep (stages 3 and 4) (1) and reflects impairment in the normal mechanisms of arousal from sleep, resulting in partial arousals during which motor behaviors are activated without full consciousness. Drug-induced somnambulism may represent a physiological state during slow-wave sleep that mimics primary somnambulism (1). Periodic leg movements of sleep may trigger sleepwalking by increasing arousal. Periodic leg movements of sleep and restless legs syndrome have been reported in conjunction with olanzapine therapy (2).
Two recent studies (3, 4) have demonstrated that olanzapine significantly increases slow-wave sleep. This is likely mediated by serotonin 5-HT2C receptor blockade because ritanserin, a 5-HT2C antagonist, increases slow-wave sleep (5). In contrast, clozapine decreases slow-wave sleep in patients with schizophrenia who were previously antipsychotic free (6).

References

1.
Charney DS, Kales A, Soldatos CR, Nelson JC: Somnambulistic-like episodes secondary to combined lithium-neuroleptic treatment. Br J Psychiatry 1979; 135:418-424
2.
Kraus T, Schuld A, Pollmacher T: Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine (letter). J Clin Psychopharmacol 1999; 19:478-479
3.
Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, Laurrabaquio MR: Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 1999; 46:141-143
4.
Sharpley AL, Vassallo CM, Cowen PJ: Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo. Biol Psychiatry 2000; 47:468-470
5.
Idzikowski C, Mills FJ, Glennard R:5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res 1986; 378:164-168
6.
Hinze-Selch D, Mullington J, Orth A, Lauer CJ, Pollmacher T: Effects of clozapine on sleep: a longitudinal study. Biol Psychiatry 1997; 42:260-266

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1158
PubMed: 11431244

History

Published online: 1 July 2001
Published in print: July 2001

Authors

Affiliations

THEODORE T. KOLIVAKIS, M.D., C.M.
HOWARD C. MARGOLESE, M.D., C.M., F.R.C.P.C.
LINDA BEAUCLAIR, M.D., F.R.C.P.C.
GUY CHOUINARD, M.D., M.SC., F.R.C.P.C.
Montreal, Que., Canada

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share